Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of BVRS-GamVac-Combi MERS Vaccine
NCT04128059Phase 2Unknown
- Start
- Nov 2019
- Primary completion
- Jul 2021
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of gam-mers-vac in Middle East respiratory syndrome (MERS). Status: unknown.
02
Drugs
gam-mers-vac
03
Conditions
Middle East respiratory syndrome (MERS)
Beyond the preview
Go deeper on NCT04128059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04128059.